 Shares of Krystal Biotech Inc NASDAQ: KRYS more than doubled on Monday after the gene therapy company said its pivotal GEM-3 trial for VYJUVEK reported positive topline results. GEM-3 trial met its primary and secondary endpoint According to Krystal Biotech, the study involving its topical treatment for Dystrophic Epidermolysis Bullosa Dystrophic EB achieved the primary ... The post Krystal Biotech shares are up 140 on Monday: heres the catalyst appeared first on Invezz. 